|
Background: In recent years, chronic heart failure (chronic heart failure, CHF) in particular ischemic cardiomyopathy heart failure morbidity and mortality is increasing every year, seriously affecting the patient's quality of life and public health. With the pathophysiological mechanisms of chronic heart failure in-depth study, people come to realize the development of heart failure is a complex series of changes in hemodynamics, ventricular remodeling and neurohumoral regulation disorders three interrelated pathophysiological mechanisms each other pathological processes. Hemodynamic abnormal activation of neuroendocrine aggravate myocardial damage sustained activation of neuroendocrine direct myocardial damage and exacerbate hemodynamic disturbances, myocardial damage, left ventricular sexual expand and failure cause hemodynamic disorders and neuroendocrine activation. Which can lead to imbalance in the blood coagulation, anti-coagulation and fibrinolytic system functions associated with endothelial dysfunction, a pathological process or state, often accompanied by changes in platelet factor easily lead to thrombosis hemorheological changes prothrombotic state (the prethrombotic state, PTS), progressive disease aggravated, thereby increasing the rate of sudden death in patients. Many studies suggest that statins have anti-the thromboembolic's role, thereby reducing the incidence of thrombosis, improve symptoms and prognosis of patients with heart failure. At present, the domestic yet to see the reports. Fasting blood extract ischemic cardiomyopathy patients with heart failure and normal control group in the study, divided into three groups, through the detection and analysis of its PTS markers levels, aims to explore: 1, normal and ischemic cardiomyopathy patients with heart failure PTS molecular markers content difference; 2, atorvastatin PTS ischemic cardiomyopathy patients with heart failure, whether influential; 3 for more effective clinical prevention and treatment of ischemic cardiomyopathy heart failure experimental basis. Methods: 66 patients with ischemic cardiomyopathy, heart failure, aged 43 to 76 years, with an average age of 65 ± 6.2 years, in line with ischemic cardiomyopathy heart failure diagnostic criteria. The inclusion the caught rule out other causes of heart failure, were randomly divided into 2 groups, atorvastatin statin therapy group and the conventional treatment group, 33 cases in each. Replacement of the normal control group of healthy volunteers (physical examination) 20 cases. The conventional treatment group using conventional heart failure therapy, atorvastatin atorvastatin 10mg night oral Atto statin therapy group on the basis of conventional treatment. All patients PTS molecular markers detected before treatment and after 4 weeks, fibrinogen (fibrinogen, Fg), von Willebrand factor (von willebrand factor, vWF), platelet a granule membrane protein (granule membrane protein- 140, GMP-140), I-type plasminogen activator inhibition factor (plasminogen activator inhibitor-1, PAI-1) changes, and the effects were compared two groups of patients. Extract all objects morning 7 to 8:00 fasting venous blood 3.6ml, 2% edetate disodium (EDTA ~ Na 2 ) anticoagulant frozen storage by ELISA detection of GMP-140, 3 % sodium citrate coagulation method for the determination Fg, and stored frozen detected by ELISA vWF and PAI-1. The test of normality (Kolmogorov-Smimov, ks), in line with the normal distribution of the measurement data are presented as mean ± standard deviation ((?) ± S) said that the groups were compared using one-way ANOVA was used to compare between the two groups t-test for paired data detecting different groups selected by PTS molecular markers, the difference was statistically significant at P <0.05. Results: 1. Compared with the control group, the plasma of patients with ischemic cardiomyopathy heart failure group Fg, vWF, GMP-140, and PAI-1 levels were significantly higher than the normal control group, the difference was statistically significant (P <0.01); Moreover, the heart failure group plasma Fg, vWF, GMP-140, and PAI-1 levels, the difference is statistically significant (P <0.01). 2. Atorvastatin plasma statin therapy patients Fg, of vWF, GMP-140 and PAI-1 levels were significantly decreased after treatment, the difference was statistically significant (P <0.05), TC, TG, LDL levels after treatment decreased trend, but the difference was not statistically significant (P> 0.05) HDL level upward trend after treatment, but the difference was not statistically significant (P> 0.05). 3. The plasma of patients with conventional treatment group Fg, vWF, GMP-140 and PAI-1 levels after treatment on a downward trend, but the difference was not statistically significant (P> 0.05). Conclusion: The results of this study suggest that (1) in patients with heart failure of ischemic cardiomyopathy form thromboembolism risk significantly higher than normal. (2) he the statins atorvastatin statins by lower PTS molecular markers, thereby reducing ischemic cardiomyopathy patients with heart failure thrombosis formation tendencies. Moreover, the improvement of the role of the PTS as early as in blood lipid regulation, therefore, this role may be independent of an important role in the Lipid Metabolism. (3) provide a test program for the treatment of patients with heart failure of ischemic cardiomyopathy basis, you can consider the application of statins in the prevention and treatment of heart failure of ischemic cardiomyopathy.
|